Excitingly, approved by the FDA, IFNβ has been used for the treatment of multiple sclerosis (MS) in clinical medicine as a cytokine with immunomodulatory properties (Cheriyan et al., 2012; Kasper and Reder, 2014). Here, IFNB1 is linked to multiple sclerosis.